These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27569840)

  • 1. MicroRNAs as CNS Drug Targets.
    Gurwitz D
    Drug Dev Res; 2016 Nov; 77(7):331-335. PubMed ID: 27569840
    [No Abstract]   [Full Text] [Related]  

  • 2. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders.
    Bhattacharya A; Ceusters M
    Neuropsychopharmacology; 2020 Jan; 45(1):234-235. PubMed ID: 31477815
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting specific cells in the brain with nanomedicines for CNS therapies.
    Zhang F; Lin YA; Kannan S; Kannan RM
    J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heteroreceptor Complexes and their Allosteric Receptor-Receptor Interactions as a Novel Biological Principle for Integration of Communication in the CNS: Targets for Drug Development.
    Fuxe K; Borroto-Escuela DO
    Neuropsychopharmacology; 2016 Jan; 41(1):380-2. PubMed ID: 26657959
    [No Abstract]   [Full Text] [Related]  

  • 8. Nanomaterial applications for neurological diseases and central nervous system injury.
    Huang L; Hu J; Huang S; Wang B; Siaw-Debrah F; Nyanzu M; Zhang Y; Zhuge Q
    Prog Neurobiol; 2017 Oct; 157():29-48. PubMed ID: 28743465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into direct nose to brain delivery: current status and future perspective.
    Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
    Hutson PH; Clark JA; Cross AJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():171-187. PubMed ID: 27575715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pericytes and the blood-brain barrier: recent advances and implications for the delivery of CNS therapy.
    Armulik A; Mäe M; Betsholtz C
    Ther Deliv; 2011 Apr; 2(4):419-22. PubMed ID: 22826851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trace amine receptors as targets for novel therapeutics: legend, myth and fact.
    Branchek TA; Blackburn TP
    Curr Opin Pharmacol; 2003 Feb; 3(1):90-7. PubMed ID: 12550748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nano-enabled delivery systems across the blood-brain barrier.
    Hwang SR; Kim K
    Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal MicroRNAs in Tissue Crosstalk.
    Gurwitz D
    Drug Dev Res; 2015 Sep; 76(6):259-62. PubMed ID: 26303125
    [No Abstract]   [Full Text] [Related]  

  • 16. Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics.
    Kalani A; Tyagi A; Tyagi N
    Mol Neurobiol; 2014 Feb; 49(1):590-600. PubMed ID: 23999871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomes as drug delivery vehicles and biomarkers for neurological and auditory systems.
    Mittal R; Bencie N; Langlie J; Mittal J; Eshraghi AA
    J Cell Physiol; 2021 Dec; 236(12):8035-8049. PubMed ID: 34224589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New methods of drug delivery through the blood brain barrier].
    Bruhn C
    Dtsch Med Wochenschr; 2012 May; 137(21):p18. PubMed ID: 22622506
    [No Abstract]   [Full Text] [Related]  

  • 19. Implantable and transdermal polymeric drug delivery technologies for the treatment of central nervous system disorders.
    Govender T; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Modi G; Naidoo D; Pillay V
    Pharm Dev Technol; 2017 Jun; 22(4):476-486. PubMed ID: 27268737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging potential of exosomes and noncoding microRNAs for the treatment of neurological injury/diseases.
    Chopp M; Zhang ZG
    Expert Opin Emerg Drugs; 2015; 20(4):523-6. PubMed ID: 26135408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.